Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 A randomized, placebo-controlled, double-blinded, crossover trial of pioglitazone for severe asthma.

Literature DB >> 28625806

A randomized, placebo-controlled, double-blinded, crossover trial of pioglitazone for severe asthma.

Maryann Kaler¹, Amisha V Barochia¹, Nargues A Weir², Rosemarie A Cuento¹, Mario Stylianou³, Mark J Roth⁴, Armando C Filie⁴, Ellen C Vaughey⁵, Steven D Nathan⁶, Stewart J Levine⁷.

Abstract

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 2017 PMID： 28625806 PMCID： PMC5723231 DOI： 10.1016/j.jaci.2017.05.033

Source DB: PubMed Journal: J Allergy Clin Immunol ISSN： 0091-6749 Impact factor: 10.793

× No keyword cloud information.

9 in total

1. The use of the peroxisome proliferator-activated receptors γ agonist rosiglitazone to treat airway hyperreactivity.

Authors: Manbir Singh Sandhu; Vesselin Dimov; Arveen Kaur Sandhu; Ryan W Walters; Tammy Wichman; Thomas Casale
Journal: Ann Allergy Asthma Immunol Date: 2012-05-24 Impact factor: 6.347

Review 2. Peroxisome proliferator-activated receptor gamma agonists as therapy for chronic airway inflammation.

Authors: Maria G Belvisi; David J Hele; Mark A Birrell
Journal: Eur J Pharmacol Date: 2006-02-03 Impact factor: 4.432

Review 3. Anti-inflammatory actions of PPAR ligands: new insights on cellular and molecular mechanisms.

Authors: Daniel S Straus; Christopher K Glass
Journal: Trends Immunol Date: 2007-11-05 Impact factor: 16.687

4. Treatment with a peroxisomal proliferator activated receptor gamma agonist has a modest effect in the allergen challenge model in asthma: a randomised controlled trial.

Authors: Duncan B Richards; Philippe Bareille; Emma L Lindo; Dean Quinn; Stuart N Farrow
Journal: Respir Med Date: 2009-11-26 Impact factor: 3.415

5. Bronchodilatory effect of the PPAR-gamma agonist rosiglitazone in smokers with asthma.

Authors: M Spears; I Donnelly; L Jolly; M Brannigan; K Ito; C McSharry; J Lafferty; R Chaudhuri; G Braganza; P Bareille; L Sweeney; I M Adcock; P J Barnes; S Wood; N C Thomson
Journal: Clin Pharmacol Ther Date: 2009-04-08 Impact factor: 6.875

6. Thiazolidinediones and the risk of asthma exacerbation among patients with diabetes: a cohort study.

Authors: Seppo T Rinne; Laura C Feemster; Bridget F Collins; David H Au; Mark Perkins; Christopher L Bryson; Thomas G O'Riordan; Chuan-Fen Liu
Journal: Allergy Asthma Clin Immunol Date: 2014-07-03 Impact factor: 3.406

7. Peroxisome proliferator activated receptor ligands as regulators of airway inflammation and remodelling in chronic lung disease.

Authors: Jane Elizabeth Ward; Xiahui Tan
Journal: PPAR Res Date: 2007 Impact factor: 4.964

8. A pilot randomized controlled trial of pioglitazone for the treatment of poorly controlled asthma in obesity.

Authors: Anne E Dixon; Meenakumari Subramanian; Michael DeSarno; Kendall Black; Lisa Lane; Fernando Holguin
Journal: Respir Res Date: 2015-11-26

9. Evaluation of the PPAR-γ Agonist Pioglitazone in Mild Asthma: A Double-Blind Randomized Controlled Trial.

Authors: J R Anderson; K Mortimer; L Pang; K M Smith; H Bailey; D B Hodgson; D E Shaw; A J Knox; T W Harrison
Journal: PLoS One Date: 2016-08-25 Impact factor: 3.240

9 in total

7 in total

A randomized, placebo-controlled, double-blinded, crossover trial of pioglitazone for severe asthma.

1. The use of the peroxisome proliferator-activated receptors γ agonist rosiglitazone to treat airway hyperreactivity.

Review 2. Peroxisome proliferator-activated receptor gamma agonists as therapy for chronic airway inflammation.

Review 3. Anti-inflammatory actions of PPAR ligands: new insights on cellular and molecular mechanisms.

4. Treatment with a peroxisomal proliferator activated receptor gamma agonist has a modest effect in the allergen challenge model in asthma: a randomised controlled trial.

5. Bronchodilatory effect of the PPAR-gamma agonist rosiglitazone in smokers with asthma.

6. Thiazolidinediones and the risk of asthma exacerbation among patients with diabetes: a cohort study.

7. Peroxisome proliferator activated receptor ligands as regulators of airway inflammation and remodelling in chronic lung disease.

8. A pilot randomized controlled trial of pioglitazone for the treatment of poorly controlled asthma in obesity.

9. Evaluation of the PPAR-γ Agonist Pioglitazone in Mild Asthma: A Double-Blind Randomized Controlled Trial.

Review 1. Exploration and Development of PPAR Modulators in Health and Disease: An Update of Clinical Evidence.

Review 2. Nonrespiratory Comorbidities in Asthma.

3. PPARγ enhances ILC2 function during allergic airway inflammation via transcription regulation of ST2.

4. Pioglitazone prevents obesity-related airway hyperreactivity and neuronal M₂ receptor dysfunction.

Review 5. The Metabolic Requirements of Th2 Cell Differentiation.

Review 6. Could Arachidonic Acid-Derived Pro-Resolving Mediators Be a New Therapeutic Strategy for Asthma Therapy?

Review 7. The Role of PPAR-γ in Allergic Disease.